Navigation Links
Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
Date:1/7/2008

rietary protein that inactivates the action of Rho, a key enzyme that prevents axon regeneration and recovery after SCI. It has been granted Orphan Drug Status in the U.S. In February 2005, enrollment began in an open-label, non-placebo-controlled, dose-escalating Phase I/IIa trial in subjects with acute SCI at sites in the United States and Canada. The trial assessed 5 dose levels of Cethrin from 0.3 mg to 9 mg in both thoracic and cervical injuries.

The trial design includes a number of post-treatment evaluations of the subjects for safety and efficacy for up to one year after treatment. The efficacy measurements assess changes in subjects' sensory and motor functions, as well as overall recovery as measured by the American Spinal Injury Association, or ASIA, Impairment Scale. The ASIA Impairment Scale is used to score subjects within five categories from A to E, with A being complete impairment with no sensory or motor function below the site of injury and E being normal. Grades B through E designate increasing levels of motor and sensory function. The subjects in the Cethrin Phase I/IIa trial suffered a complete thoracic or cervical SCI and were thus classified as an A on the ASIA Impairment Scale at the time of enrollment in the trial.

The 6-month interim data on 37 of these subjects treated with doses of up to 6 mg indicate that 27% of the Cethrin treated subjects improved from ASIA A to ASIA B or better. This is more than 400% greater than the conversion rate seen with the standard of care in a similarly designed study reported by Burns and colleagues in the Journal of Neurotrauma. When subjects with cervical injuries who were treated with Cethrin were analyzed separately, about 46% of the subjects exhibited a conversion rate from ASIA A to ASIA B or better. Moreover, about 18% of subjects overall and 38% of subjects with cervical injuries improved to ASIA C or better over the six months the hallmark of which is recovery of some motor function.
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
2. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
3. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
4. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
5. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
6. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
7. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
8. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
11. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... , Oct. 1, 2014 The global high ... marked by the ,Threat of Obsolescence, wherein technologies as ... rapidly. Pharmaceutical and biotechnology companies as well as academic ... content screening as a powerful research tool in drug ... fastest-growing segment in the high content screening market. In ...
(Date:10/1/2014)... 1, 2014   Plexus Information Systems, Inc. ... Information Management Systems (AIMS), announced a partnership with ... wholly owned subsidiary of Quality Systems, Inc. and ... connectivity solutions.  Logo - ... This partnership extends the NextGen Healthcare ...
(Date:10/1/2014)... NEW YORK , October 1, 2014 ... provider for the medical industries, announced today the expansion of its ... New York City . genae Americas was incorporated in 2011. ... centered in one of the highest concentrations of medical innovation and ... , President at genae Americas. "The expansion of genae from ...
Breaking Medicine Technology:High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 2High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 3Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3genae Opens Offices in New York City 2
... SILVER SPRING, Md., June 8, 2011 The Food and ... containing 80 mg of simvastatin — the highest approved dose ... of the risk of muscle injury. (Logo:   ... only be used by patients who have been taking it ...
... Merz Pharmaceuticals today announced that new data on ... from accessory (complexing) proteins, will be presented at ... of Parkinson,s Disease and Movement Disorders in Toronto, ... XEOMIN were safe and effective in the treatment ...
Cached Medicine Technology:FDA CONSUMER HEALTH INFORMATION - Limit Use of 80 mg Simvastatin 2New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinson's Disease And Movement Disorders (MDS) 2New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinson's Disease And Movement Disorders (MDS) 3
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... roses -- literally -- may face an increased risk of dying ... study of over 3,000 older Americans, researchers found those who were ... more than three times as likely to die in the next ... In fact, anosmia -- the inability to distinguish odors -- was ...
(Date:10/1/2014)... University of Adelaide have developed a model that could ... outcome from treatment - from their very first psychotic ... of factors, including clinical symptoms, cognitive abilities, MRI scans ... blood. , Speaking in the lead up to World ... Psychiatry , Professor Bernhard Baune , says ...
(Date:10/1/2014)... the brain of a rat and a robot could ... QUT leading robotics researcher. , Dr Michael Milford ... study uses new computer algorithms to enable robots to ... "This is a very Frankenstein type of project," Dr ... thing together because we,re taking the eyes of a ...
(Date:10/1/2014)... people to keep their "eyes on the prize" may ... walking, staying focused on a specific target ahead can ... people walk there faster, psychology researchers have found. Their ... around the environment naturally, offers a new strategy to ... interested in exercise if physical activity seems daunting, which ...
(Date:10/1/2014)... October 01, 2014 Bedros Keuilian is ... Boot Camp fitness boot camps, he’s also considered the ... , with sold out business summits, a line of ... consultant to a recent Spike TV reality show to ... now is the time for personal trainers and fitness ...
Breaking Medicine News(10 mins):Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Predicting the future course of psychotic illness 2Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3
... the #1 co-ed,fitness club chain in the world, has ... has clubs operating in 46 states, Canada and Australia,serving ... other well-known fitness chains have recently scaled back their,expansion ... grow at,an impressive rate. In fact, in the past ...
... the eye region is also useful when trying to spot fatigue ... or less tired? Focus on the area around your eyes, a ... your age and level of fatigue. , When asked to ... looked at the eye region almost half the time, researchers ...
... profound impact on this country,s psyche. Eight years after ... events affected us. A number of studies have shown ... the terrorist attacks experienced heightened levels of stress and ... Research has also indicated that elevated levels of stress ...
... PARK, N.J. and NEW YORK, Feb. 2 HLTH Corporation ... subsidiary, WebMD Health Corp. (Nasdaq: WBMD ), today ... the three months ended December 31, 2008 at approximately 4:00 ... will host a conference call at 4:45 pm (ET) on ...
... SCOLR Pharma, Inc. (NYSE Alternext US: DDD) today announced ... Ph.D., M.B.A., to serve as president and chief executive officer. ... SCOLR Pharma board of directors since August 2007.Michael N. Taglich, ... very pleased that Dr. Morra has agreed to become SCOLR ...
... (TFAH) strongly supports President Obama,s call for a "complete ... outbreak of Salmonella tied to peanut butter ... Salmonella outbreaks in 2008 highlight the need ... released a comprehensive report, Fixing Food Safety: Protecting ...
Cached Medicine News:Health News:Anytime Fitness Opens 1,000th Club 2Health News:Anytime Fitness Opens 1,000th Club 3Health News:When Gauging Age, the Eyes Have It 2Health News:Driving under the influence (of stress): Regional effects of 9/11 attacks on driving 2Health News:HLTH and WebMD Announce Fourth Quarter Earnings Release Date and Conference Call 2Health News:SCOLR Pharma, Inc. Announces Appointment of Bruce S. Morra, Ph.D., as President & CEO 2Health News:SCOLR Pharma, Inc. Announces Appointment of Bruce S. Morra, Ph.D., as President & CEO 3Health News:Trust for America's Health Applauds President Obama's Call for a Complete Review of the U.S. Food Safety System 2Health News:Trust for America's Health Applauds President Obama's Call for a Complete Review of the U.S. Food Safety System 3
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes....
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
The AMY method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of amylase activity in serum, plasma and urine....
Enzymatic Clearance assay for the in vitro quantitative determination of LDL-cholesterol in human serum and plasma....
Medicine Products: